Neumora Therapeutics Reports Q1 Loss Amid Progress in Brain Disease Therapies
Neumora Therapeutics reported a net loss of $68 million in Q1 2025, but remains committed to developing targeted therapies for brain diseases despite financial challenges.
2 minutes to read